The Relation of Vitamin D Blood Level with Statin-Associated Muscle Symptoms (SAMS)
International Neuropsychiatric Disease Journal,
Aims: This work evaluates the vitamin D status in patients with statins- associated muscle symptoms.
Study Design: A case control prospective study.
Place and Duration of Study: Neurology Department, Mansoura University, Mansoura, Egypt, between June 2020 and May 2021.
Methodology: Total of 85 participants included in this study, 60 participants of them have chronic Stroke and ischemic heart disease, treated by different kinds of statins and 25 participants were healthy controlled individuals. The 60 patients were 35 males (55%) and 25 females (45%), with age ranging from 40 to 70 years. The 60 participants were divided into two groups: The first group included (30 patients) treated with statins and they did not have Statin-Associated Muscle Symptoms (SAMS).The second group included (30 patients) also treated with Statin and they complained of SAMS. The third group is the control group, which contains the 25 participants who were healthy people. The control group included15 males (55%) and 10 females (45%) with age ranged from 35 to 65 years. Laboratory investigations were conducted on all participants in this study. The participants were subjected to total of 5 laboratory tests, which include: (1) Vitamin D (Enzyme immunoassay method), (2) Total CK (Enzymatic method), (3) Total Cholesterol and Triglycerides (Enzymatic method), (4)High density lipoproteins Cholesterol (Precipitation method), (4)Low density lipoproteins Cholesterol (Freid Wald equation), and (5) C – reactive protein (CRP: Latex Agglutination Method) was done beside elecetrophysiology study ( Needle electromyography (NEMG) was include).
Results: Out of 60 patients the statistical readings of Vitamin D levels for the studied groups, demonstrating a significant statistical difference in Vitamin D levels between patients complaining of statin-associated muscle symptoms group (P≤0.001), and the other groups with lowest mean of (26.30 ±3.75), while patient without statin-associated muscle symptom group had the mean rating of (29.33 ±3.69), and the control group had the highest mean of (30.14 ±3.57).
Conclusion: There is a positive relationship between vitamin D deficiency and statin-associated muscle symptoms. Vitamin D status may play an important role in diagnosis and management of SAMS. Further studies are needed to evaluate the relationship between vitamin D and SAMS.
- The relation
- vitamin D blood level
- Statin-Associated Muscle Symptoms (SAMS)
How to Cite
Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology. 2013,2014;63(25 Part B):2889-2934.
Vrablik M, Zlatohlavek L, Stulc T, Adamkova V, Prusikova M, Schwarzova L, et al. Statin-associated myopathy: From genetic predisposition to clinical management. Physiological Research. 2014;63:S327.
Holick MF. High prevalence of vitamin D inadequacy and implications for health. In Mayo Clinic Proceedings. 2006;81(3):353-373.
Pasternak RC, Smith SC, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Journal of the American College of Cardiology. 2002;40(3):567-572.
Rosenson RS, Baker SK, Jacobson TA, Kopecky SL, Parker BA. An assessment by the statin muscle safety task force: 2014 update. Journal of Clinical Lipidology. 2014;8(3):S58-S71.
Holick MF. Vitamin D deficiency. New England Journal of Medicine. 2007;357(3):266-281.
Brown AJ, Ikonen E, Olkkonen VM. Cholesterol precursors: More than mere markers of biosynthesis. Current Opinion in Lipidology. 2014;25(2):133-139.
Pennisi M, Di Bartolo G, Malaguarnera G, Bella R, Lanza G, Malaguarnera M. Vitamin D serum levels in patients with statin-induced musculoskeletal pain. Disease Markers; 2019.
Gunton JE, Girgis CM. Vitamin D and muscle. Bone Reports. 2018;8:163-167.
Jacobson TA, Cheeley MK, Jones PH, La Forge R, Maki KC, López JAG, et al. The STatin adverse treatment experience survey: experience of patients reporting side effects of statin therapy. J Clin Lipidol. 2019;13(3):415–24.
Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyper-lipidemic patients the PRIMO study. J Cardiovasc Drugs Ther. 2005;19(6):403–14.
Moghadam-Kia S, Oddis CV, Aggarwal R. Approach to asymp-tomatic creatine kinase elevation. Cleve Clin J Med. 2016;83(1):37–42.
Cham S, Evans MA, Denenberg JO, Golomb BA. Statin-associated muscle-related adverse effects: a case series of 354 patients. J Pharmacotherapy. 2010;30(6):541-53.
Mammen AL, Amato AA. Statin myopathy: A review of recent progress. J Current Opinion in Rheumatology. 2010;22:644–50.
Robien K, Oppeneer SJ, Kelly JA, Hamilton-Reeves JM. Drug-vitamin D interactions: A systematic review of the literature. J Nutr Clin Pract. 2013;28:194-208.
Newman CB, Preiss D, Tobert JA, Jacobson TA, Page RL, Goldstein LB, et al. Statin safety and associated adverse events: a scientific statement from the American Heart Association. J Arterioscler Thromb Vasc Biol. Most up to Date AHA Guidelines on Statin Safety. 2019;39(2):E38–81.
Roche VF. Antihyperlipidemic statins: A self-contained, clinically relevant medicinal chemistry lesson. American Journal of Pharmaceutical Education. 2005;69(1-5):546.
Herman RJ. Drug interactions and the statins. CMAJ. 1999;161:1281–6.
Drocourt L, Ourlin JC, Pascussi JM, Maurel P, Vilarem MJ. Expression of CYP3A4, CYP2B6, and CYP2C9 is regulated by the vitamin D receptor pathway in primary human hepatocytes. J Biol Chem. 2002;277:25125–132.
Bhattacharyya S, Bhattacharyya K, Maitra A. Possible mechanisms of interaction between statins and vitamin D. J. Qjm. 2012;105(5):487-491.
Horn M. Coadministration of itraconazole with hypolipidemic agents may induce Rhabdomyolysis in Healthy Individuals. 1996;132:1254.
Riche KD, Arnall J, Rieser K, East HE, Riche DM. Impact of vitamin D status on statin-induced myopathy. Journal of Clinical and Translational Endocrinology. 2016;6:56-59.
Bischoff‐Ferrari HA, Fischer K, Orav EJ, Dawson‐Hughes B, Meyer U, Chocano‐Bedoya PO, et al. Statin use and 25‐hydroxyvitamin D blood level response to vitamin D treatment of older adults. Journal of the American Geriatrics Society. 2017;65(6): 1267-1273.
Pérez-Castrillón JL, Abad Manteca L, Vega G, del Pino Montes J, de Luis D, Dueňas Laita A. Vitamin D levels and lipid response to atorvastatin. International Journal of Endocrinology;2010.
Rejnmark L, Vestergaard P. Heickendorff L, Mosekilde L. Simvastatin does not affect vitamin d status, but low vitamin d levels are associated with dyslipidemia: Results from a randomised, controlled trial. International Journal of Endocrinology; 2010.
Thabit K, Alhifany A, Alsheikh A, Namnqani R, Al-Mohammadi S, Elmorsy AS, et al. Effect of simvastatin and atorvastatin on serum vitamin d and bone mineral density in hypercholesterolemic patients: A cross-sectional study. Journal of Osteoporosis; 2014.
Anagnostis P, Adamidou F, Slavakis A, Polyzos SA, Selalmatzidou D, Panagiotou A, et al. Comparative effect of atorvastatin and rosuvastatin on 25-hydroxy-vitamin D levels in non-diabetic patients with dyslipidaemia: A prospective randomized open-label pilot study. The Open Cardiovascular Medicine Journal. 2014;8:55.
Staal A, Frith JC, French MH, Swartz J, Güngör T, Harrity TW, et al. The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG‐CoA reductase activity. Journal of Bone and Mineral Research. 2003; 18(1):88-96.
Verdoia M, Pergolini P, Rolla R, Nardin M, Schaffer A, Barbieri L. Novara Atherosclerosis Study Group. Impact of high-dose statins on vitamin D levels and platelet function in patients with coronary artery disease. Thrombosis Research. 2017;150:90-95.
Thabit A, Alhifany R, Alsheikh S. Namnqani A, Al-Mohammadi S, Elmorsy M, et al. Effect of simvastatin and atorvastatin on serum vitamin D and bone mineral density in hypercholesterolemic patients: A cross-sectional study, J. Osteoporos. 2014;468397.
Anagnostis F, Adamidou A, Slavakis SA, Polyzos D, Selalmatzidou A, Panagiotou VG, et al. Comparative effect of atorvastatin androsuvastatin on 25-hydroxy-vitamin D levels in non-diabetic patients with dyslipidaemia: A prospective randomized open-label pilot study, Open Cardiovasc. Med. J. 2014;8:55–60.
Tudorancea AD, Ciurea PL, Parvanescu CD, Firulescu SC, Bogdan C, Vintila EM, et al. differential diagnosis between statin myotoxicity and inflammatory myositis-case presentation. Romanian Journal of Rheumatology. 2018;27(3).
Zuppa A, De Michelis C, Meo G, Prada V, Gemelli C, Infantino M, et al. Maintenance treatment with subcutaneous immunoglobulins in the long-term management of anti-HMCGR myopathy. Neuromuscular Disorders. 2021;31(2):134-138.
Abstract View: 52 times
PDF Download: 37 times